ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients
The Journal of Infectious Diseases · 31.08.2023 · 228 (Supplement_2) · S77-S82
DOI: 10.1093/infdis/jiad246 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 31.08.2023. Verfasst von Judith S Currier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA.
- Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
- Department of Medicine, University of California, San Diego, La Jolla, California, USA.
- Division of AIDS, National Institutes of Health, Rockville, Maryland, USA.
- Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
ORCID-Profile: Judith S Currier, Carlee Moser
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Currier, J. S., Moser, C., Eron, J. J., Chew, K. W., Smith, D. M., Javan, A. C., Wohl, D. A., Daar, E. S., Hughes, M. D., & ACTIV-2/A5401 Study Team (2023). ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. The Journal of Infectious Diseases, 228(Supplement_2), S77-S82. https://doi.org/10.1093/infdis/jiad246
Vancouver
Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, et al. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. The Journal of Infectious Diseases. 2023;228(Supplement_2):S77-S82. doi:10.1093/infdis/jiad246
BibTeX
@article{Currier2023,
author = {Currier, Judith S and Moser, Carlee and Eron, Joseph J and Chew, Kara W and Smith, Davey M and Javan, Arzhang Cyrus and Wohl, David Alain and Daar, Eric S and Hughes, Michael D and ACTIV-2/A5401 Study Team, ACTIV-2/A5401 Study Team},
title = {ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {228},
number = {Supplement_2},
pages = {S77--S82},
doi = {10.1093/infdis/jiad246}
}
EUVIMED